Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579)

R. H. Creech, D. Tritchler, D. S. Ettinger, J. A. Ferraro, J. C. Ruckdeschel, S. E. Vogl, J. Woll

Research output: Contribution to journalArticlepeer-review

Abstract

Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PALA, amsacrine, teniposide, and zinostatin. Of the 66 evaluable patients, one partial response occurred among 17 patients treated with teniposide and no responses occurred with the other drugs. Two patients each treated with amsacrine and teniposide experienced life-threatening hematologic toxic effects and one patient treated with zinostatin died of thrombocytopenic pulmonary hemorrhage. The overall median patient survival was 9.6 weeks. Weight loss ≥ 5% prior to therapy, extensive disease, and a nomambulatory status were associated with poor survival.

Original languageEnglish (US)
Pages (from-to)1183-1184
Number of pages2
JournalCancer treatment reports
Volume68
Issue number9
StatePublished - 1984
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579)'. Together they form a unique fingerprint.

Cite this